These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 29941635)

  • 1. UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria.
    Brunschwig C; Lawrence N; Taylor D; Abay E; Njoroge M; Basarab GS; Le Manach C; Paquet T; Cabrera DG; Nchinda AT; de Kock C; Wiesner L; Denti P; Waterson D; Blasco B; Leroy D; Witty MJ; Donini C; Duffy J; Wittlin S; White KL; Charman SA; Jiménez-Díaz MB; Angulo-Barturen I; Herreros E; Gamo FJ; Rochford R; Mancama D; Coetzer TL; van der Watt ME; Reader J; Birkholtz LM; Marsh KC; Solapure SM; Burke JE; McPhail JA; Vanaerschot M; Fidock DA; Fish PV; Siegl P; Smith DA; Wirjanata G; Noviyanti R; Price RN; Marfurt J; Silue KD; Street LJ; Chibale K
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29941635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of 6'-chloro-N-methyl-5'-(phenylsulfonamido)-[3,3'-bipyridine]-5-carboxamide (CHMFL-PI4K-127) as a novel Plasmodium falciparum PI(4)K inhibitor with potent antimalarial activity against both blood and liver stages of Plasmodium.
    Liang X; Jiang Z; Huang Z; Li F; Chen C; Hu C; Wang W; Hu Z; Liu Q; Wang B; Wang L; Qi Z; Liu J; Jiang L; Liu Q
    Eur J Med Chem; 2020 Feb; 188():112012. PubMed ID: 31911293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erratum for Brunschwig et al., "UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria".
    Brunschwig C; Lawrence N; Taylor D; Abay E; Njoroge M; Basarab GS; Le Manach C; Paquet T; Gonzàlez Cabrera D; Nchinda AT; de Kock C; Wiesner L; Denti P; Waterson D; Blasco B; Leroy D; Witty MJ; Donini C; Duffy J; Wittlin S; White KL; Charman SA; Jiménez-Díaz MB; Angulo-Barturen I; Herreros E; Gamo FJ; Rochford R; Mancama D; Coetzer TL; van der Watt ME; Reader J; Birkholtz LM; Marsh KC; Solapure SM; Burke JE; McPhail JA; Vanaerschot M; Fidock DA; Fish PV; Siegl P; Smith DA; Wirjanata G; Noviyanti R; Price RN; Marfurt J; Silue KD; Street LJ; Chibale K
    Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30355750
    [No Abstract]   [Full Text] [Related]  

  • 4. Characterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Dose-Efficacy Modeling.
    Le Bihan A; de Kanter R; Angulo-Barturen I; Binkert C; Boss C; Brun R; Brunner R; Buchmann S; Burrows J; Dechering KJ; Delves M; Ewerling S; Ferrer S; Fischli C; Gamo-Benito FJ; Gnädig NF; Heidmann B; Jiménez-Díaz MB; Leroy D; Martínez MS; Meyer S; Moehrle JJ; Ng CL; Noviyanti R; Ruecker A; Sanz LM; Sauerwein RW; Scheurer C; Schleiferboeck S; Sinden R; Snyder C; Straimer J; Wirjanata G; Marfurt J; Price RN; Weller T; Fischli W; Fidock DA; Clozel M; Wittlin S
    PLoS Med; 2016 Oct; 13(10):e1002138. PubMed ID: 27701420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a Potential Antimalarial Drug Candidate from a Series of 2-Aminopyrazines by Optimization of Aqueous Solubility and Potency across the Parasite Life Cycle.
    Le Manach C; Nchinda AT; Paquet T; Gonzàlez Cabrera D; Younis Y; Han Z; Bashyam S; Zabiulla M; Taylor D; Lawrence N; White KL; Charman SA; Waterson D; Witty MJ; Wittlin S; Botha ME; Nondaba SH; Reader J; Birkholtz LM; Jiménez-Díaz MB; Martínez MS; Ferrer S; Angulo-Barturen I; Meister S; Antonova-Koch Y; Winzeler EA; Street LJ; Chibale K
    J Med Chem; 2016 Nov; 59(21):9890-9905. PubMed ID: 27748596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of
    Cheuka PM; Centani L; Arendse LB; Fienberg S; Wambua L; Renga SS; Dziwornu GA; Kumar M; Lawrence N; Taylor D; Wittlin S; Coertzen D; Reader J; van der Watt M; Birkholtz LM; Chibale K
    ACS Infect Dis; 2021 Jan; 7(1):34-46. PubMed ID: 33319990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro dual activity of Aloe marlothii roots and its chemical constituents against Plasmodium falciparum asexual and sexual stage parasites.
    Mianda SM; Invernizzi L; van der Watt ME; Reader J; Moyo P; Birkholtz LM; Maharaj VJ
    J Ethnopharmacol; 2022 Oct; 297():115551. PubMed ID: 35850311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of FNDR-20123, a histone deacetylase inhibitor for the treatment of Plasmodium falciparum malaria.
    Potluri V; Shandil RK; Gavara R; Sambasivam G; Campo B; Wittlin S; Narayanan S
    Malar J; 2020 Oct; 19(1):365. PubMed ID: 33046062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of 4-Amino 2-Anilinoquinazolines against
    Gilson PR; Nguyen W; Poole WA; Teixeira JE; Thompson JK; Guo K; Stewart RJ; Ashton TD; White KL; Sanz LM; Gamo FJ; Charman SA; Wittlin S; Duffy J; Tonkin CJ; Tham WH; Crabb BS; Cooke BM; Huston CD; Cowman AF; Sleebs BE
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30559138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimalarial efficacy of MMV390048, an inhibitor of
    Paquet T; Le Manach C; Cabrera DG; Younis Y; Henrich PP; Abraham TS; Lee MCS; Basak R; Ghidelli-Disse S; Lafuente-Monasterio MJ; Bantscheff M; Ruecker A; Blagborough AM; Zakutansky SE; Zeeman AM; White KL; Shackleford DM; Mannila J; Morizzi J; Scheurer C; Angulo-Barturen I; Martínez MS; Ferrer S; Sanz LM; Gamo FJ; Reader J; Botha M; Dechering KJ; Sauerwein RW; Tungtaeng A; Vanachayangkul P; Lim CS; Burrows J; Witty MJ; Marsh KC; Bodenreider C; Rochford R; Solapure SM; Jiménez-Díaz MB; Wittlin S; Charman SA; Donini C; Campo B; Birkholtz LM; Hanson KK; Drewes G; Kocken CHM; Delves MJ; Leroy D; Fidock DA; Waterson D; Street LJ; Chibale K
    Sci Transl Med; 2017 Apr; 9(387):. PubMed ID: 28446690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Malarial PI4K inhibitor induced diaphragmatic hernias in rat: Potential link with mammalian kinase inhibition.
    Demarta-Gatsi C; Donini C; Duffy J; Sadler C; Stewart J; Barber JA; Tornesi B
    Birth Defects Res; 2022 Jun; 114(10):487-498. PubMed ID: 35416431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone methyltransferase inhibitors are orally bioavailable, fast-acting molecules with activity against different species causing malaria in humans.
    Malmquist NA; Sundriyal S; Caron J; Chen P; Witkowski B; Menard D; Suwanarusk R; Renia L; Nosten F; Jiménez-Díaz MB; Angulo-Barturen I; Santos Martínez M; Ferrer S; Sanz LM; Gamo FJ; Wittlin S; Duffy S; Avery VM; Ruecker A; Delves MJ; Sinden RE; Fuchter MJ; Scherf A
    Antimicrob Agents Chemother; 2015 Feb; 59(2):950-9. PubMed ID: 25421480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical characterization and target validation of the antimalarial pantothenamide MMV693183.
    de Vries LE; Jansen PAM; Barcelo C; Munro J; Verhoef JMJ; Pasaje CFA; Rubiano K; Striepen J; Abla N; Berning L; Bolscher JM; Demarta-Gatsi C; Henderson RWM; Huijs T; Koolen KMJ; Tumwebaze PK; Yeo T; Aguiar ACC; Angulo-Barturen I; Churchyard A; Baum J; Fernández BC; Fuchs A; Gamo FJ; Guido RVC; Jiménez-Diaz MB; Pereira DB; Rochford R; Roesch C; Sanz LM; Trevitt G; Witkowski B; Wittlin S; Cooper RA; Rosenthal PJ; Sauerwein RW; Schalkwijk J; Hermkens PHH; Bonnert RV; Campo B; Fidock DA; Llinás M; Niles JC; Kooij TWA; Dechering KJ
    Nat Commun; 2022 Apr; 13(1):2158. PubMed ID: 35444200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized feasibility trial comparing four antimalarial drug regimens to induce
    Reuling IJ; van de Schans LA; Coffeng LE; Lanke K; Meerstein-Kessel L; Graumans W; van Gemert GJ; Teelen K; Siebelink-Stoter R; van de Vegte-Bolmer M; de Mast Q; van der Ven AJ; Ivinson K; Hermsen CC; de Vlas S; Bradley J; Collins KA; Ockenhouse CF; McCarthy J; Sauerwein RW; Bousema T
    Elife; 2018 Feb; 7():. PubMed ID: 29482720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Triazolopyrimidine-Based Dihydroorotate Dehydrogenase Inhibitor with Improved Drug-like Properties for Treatment and Prevention of Malaria.
    Phillips MA; White KL; Kokkonda S; Deng X; White J; El Mazouni F; Marsh K; Tomchick DR; Manjalanagara K; Rudra KR; Wirjanata G; Noviyanti R; Price RN; Marfurt J; Shackleford DM; Chiu FC; Campbell M; Jimenez-Diaz MB; Bazaga SF; Angulo-Barturen I; Martinez MS; Lafuente-Monasterio M; Kaminsky W; Silue K; Zeeman AM; Kocken C; Leroy D; Blasco B; Rossignol E; Rueckle T; Matthews D; Burrows JN; Waterson D; Palmer MJ; Rathod PK; Charman SA
    ACS Infect Dis; 2016 Dec; 2(12):945-957. PubMed ID: 27641613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study.
    Llanos-Cuentas A; Casapia M; Chuquiyauri R; Hinojosa JC; Kerr N; Rosario M; Toovey S; Arch RH; Phillips MA; Rozenberg FD; Bath J; Ng CL; Cowell AN; Winzeler EA; Fidock DA; Baker M; Möhrle JJ; Hooft van Huijsduijnen R; Gobeau N; Araeipour N; Andenmatten N; Rückle T; Duparc S
    Lancet Infect Dis; 2018 Aug; 18(8):874-883. PubMed ID: 29909069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood-stage antiplasmodial activity and oocyst formation-blockage of metallo copper-cinchonine complex.
    Morais CMG; Brito RMM; Weselucha-Birczyńska A; Pereira VSS; Pereira-Silva JW; Menezes A; Pessoa FAC; Kucharska M; Birczyńska-Zych M; Ríos-Velásquez CM; de Andrade-Neto VF
    Front Cell Infect Microbiol; 2022; 12():1047269. PubMed ID: 36530433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of quinolone antimalarials targeting the Plasmodium falciparum mitochondrial respiratory chain for the treatment and prophylaxis of malaria.
    Biagini GA; Fisher N; Shone AE; Mubaraki MA; Srivastava A; Hill A; Antoine T; Warman AJ; Davies J; Pidathala C; Amewu RK; Leung SC; Sharma R; Gibbons P; Hong DW; Pacorel B; Lawrenson AS; Charoensutthivarakul S; Taylor L; Berger O; Mbekeani A; Stocks PA; Nixon GL; Chadwick J; Hemingway J; Delves MJ; Sinden RE; Zeeman AM; Kocken CH; Berry NG; O'Neill PM; Ward SA
    Proc Natl Acad Sci U S A; 2012 May; 109(21):8298-303. PubMed ID: 22566611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PI4 Kinase Is a Prophylactic but Not Radical Curative Target in Plasmodium vivax-Type Malaria Parasites.
    Zeeman AM; Lakshminarayana SB; van der Werff N; Klooster EJ; Voorberg-van der Wel A; Kondreddi RR; Bodenreider C; Simon O; Sauerwein R; Yeung BK; Diagana TT; Kocken CH
    Antimicrob Agents Chemother; 2016 May; 60(5):2858-63. PubMed ID: 26926645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MEFAS, a hybrid of artesunate-mefloquine active against asexual stages of Plasmodium vivax in field isolates, inhibits malaria transmission.
    Penna-Coutinho J; da Silva Araújo M; Campos Aguiar AC; Sá PM; Rios CT; Medeiros JF; Pereira DB; Boechat N; Krettli AU
    Int J Parasitol Drugs Drug Resist; 2021 Dec; 17():150-155. PubMed ID: 34637981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.